SAN ANTONIO / May 20, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical... Read More

CyPath ® Lung sales up 276% year-over-year SAN ANTONIO / May 15, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended March 31, 2025. Key Highlights Generated revenue of $1.9 million in the first... Read More

Dr. Gordon Downie shares case-based evidence demonstrating how CyPath® Lung improves diagnostic confidence and guides care in high-risk patients SAN ANTONIO / May 08, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced the release of a white paper authored by Dr.... Read More

SAN ANTONIO / May 07, 2025 / Business Wire / bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other... Read More

SAN ANTONIO / May 06, 2025 / Business Wire / bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by... Read More

Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection. SAN ANTONIO / Apr 17, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced implementation of key efficiency... Read More

Increased Demand, Expanded Insurance Coverage Drive Record Growth SAN ANTONIO / Mar 31, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2024. 2024 Highlights Record Revenue: Revenue grew... Read More

Case Demonstrates Benefit of Integrating CyPath ® Lung into Standard of Care for Patients Under Surveillance After Treatment for Previous Lung Cancer SAN ANTONIO / Mar 26, 2025 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) today released a case study in which a positive CyPath ® Lung result led to the detection of a second primary lung cancer in a high-risk patient who was previously diagnosed with... Read More

Case Demonstrates CyPath® Lung’s Potential in Guiding Oncological Care SAN ANTONIO / Mar 19, 2025 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung microenvironment identified a hidden recurrence of breast cancer in an 80-year-old high-risk patient. “This case exemplifies how CyPath® Lung can play... Read More

SAN ANTONIO / Mar 13, 2025 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) announced the release of physicians’ case studies showing the benefit to patients and their doctors of using CyPath ® Lung , the Company’s noninvasive test for early detection of lung cancer. CyPath ® Lung’s test result of “Unlikely Lung Cancer” directly prevented a robotic bronchoscopic biopsy or high-risk percutaneous biopsy... Read More

Proactive steps reinforce bioAffinity Technologies’ laser focus on accelerating CyPath® Lung sales growth in strategic national markets Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath® Lung personnel at Company’s subsidiary laboratory SAN ANTONIO / Mar 06, 2025 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for... Read More

SAN ANTONIO / Feb 26, 2025 / Business Wire / bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has closed its previously announced warrant exercise agreements with four existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company’s shares of common stock (the “Existing Warrants”). In consideration for the immediate exercise in full of the... Read More

SAN ANTONIO / Feb 25, 2025 / Business Wire / bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company’s shares of common stock (the “Existing Warrants”). In consideration for the immediate exercise in full of the Existing Warrants... Read More

SAN ANTONIO / Jan 22, 2025 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Australian Patent Office (IP Australia), has accepted bioAffinity’s patent application for the method of predicting the likelihood of lung cancer used by the CyPath ®... Read More

SAN ANTONIO / Jan 13, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported the results of the Company’s CyPath ® Lung pilot marketing program using Texas for our beta launch with sales of more than 600 tests delivered in 2024. “We are extremely pleased with the... Read More

SAN ANTONIO / Dec 17, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, invites investors to a webinar on Dec. 19, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature bioAffinity President and CEO Maria Zannes who will share insight into how the Company... Read More

Noninvasive CyPath ® Lung test for lung cancer contributes to growing revenues SAN ANTONIO / Dec 12, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today reported that the successful execution of its pilot marketing program and steady growth in sales of the CyPath® Lung test for early... Read More

SAN ANTONIO / Dec 05, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint presentation highlighting the Veterans Health Administration (VHA) award adding CyPath ® Lung to the FSS procurement system for the VA’s 1,380 healthcare... Read More

Expanded CyPath ® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician offices signed increased 75% over Q2 2024 Reaffirmed $9.6 million 2024 revenue forecast for wholly owned Precision Pathology subsidiary SAN ANTONIO / Nov 14, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the... Read More

Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel SAN ANTONIO / Nov 04, 2024 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) (“bioAffinity” or the “Company”), a biotechnology company focused on the need for noninvasive tests for the detection of... Read More

SAN ANTONIO / Oct 30, 2024 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Certificate of Grant of Patent to bioAffinity Technologies for the method of predicting the likelihood of lung cancer used by the... Read More

SAN ANTONIO / Oct 21, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and... Read More

SAN ANTONIO / Oct 18, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 2,048,294 shares (the “Shares”) of common stock in a registered direct offering at a price of... Read More

bioAffinity VP served on expert panel that published new guidance SAN ANTONIO / Oct 16, 2024 / Business Wire / bioAffinity Technologies ’ (Nasdaq: BIAF; BIAFW) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the peer-reviewed paper, “Implementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is... Read More

Edwards rejoins the Company after serving as interim CFO SAN ANTONIO / Oct 10, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that J. Michael Edwards has accepted the position of Chief Financial Officer (CFO). Edwards has been bioAffinity’s interim CFO since Sept. 15 and... Read More

Noninvasive diagnostic test for lung cancer available to U.S. Veterans, other federal health services patients SAN ANTONIO / Oct 09, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that CyPath ® Lung , its noninvasive test to detect early-stage lung cancer, will be added to... Read More

Study by BAMC’s Michael Morris, M.D., and VA’s Sheila Habib, M.D., evaluated potential economic impact of CyPath® Lung for the early detection of lung cancer SAN ANTONIO, Texas / Sep 18, 2024 / Business Wire / A new economic study found that adding CyPath® Lung , bioAffinity Technologies’ noninvasive test for detection of early-stage lung cancer, to the standard of care for Medicare patients with a positive lung cancer... Read More

Edwards held CFO position at bioAffinity for nine years, leading Company through successful IPO SAN ANTONIO / Aug 23, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that Michael Dougherty has resigned as Chief Financial Officer to accept a CFO position in the Pacific... Read More

Q2 CyPath ® Lung test sales up 217% over Q1 2024 Expanded CyPath ® Lung test sales to physicians in California and Ohio; now receiving orders from physicians in eight states outside of Texas Raised full-year CyPath ® Lung sales forecast for test marketing program by 85% during the second quarter SAN ANTONIO, Texas / Aug 14, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company... Read More

SAN ANTONIO / Aug 05, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW) announced today that pursuant to warrant exercise agreements dated Aug. 2, 2024, three existing accredited investors have exercised outstanding warrants to purchase an aggregate of 1,041,667 of the Company’s shares of common stock (“Existing Warrants”) at an exercise price that was reduced from $1.64 to $1.25 per share for gross... Read More

SAN ANTONIO / Aug 02, 2024 / Business Wire / bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 1,041,667 of the Company’s shares of common stock (the “Existing Warrants”). In consideration for the immediate exercise in full of the Existing Warrants... Read More

Sales of CyPath ® Lung tests continue to accelerate as sales team expands customer base of pulmonology practices SAN ANTONIO / Jul 09, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today raised its full-year forecast for sales of CyPath ® Lung in the Company’s test marketing program by 85%... Read More

Sales of CyPath® Lung tests, onboarding of pathology practices ahead of forecasts SAN ANTONIO / Jun 12, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported 139% growth in the number of pulmonology practices and physicians offering CyPath® Lung to patients since... Read More

Expanded, experienced sales team more than doubles number of physician practices ordering CyPath® Lung test year-to-date More than 547% annualized growth rate for CyPath® Lung orders in first four months of 2024 over full-year 2023, leading to 35% increase in original 2024 forecast KOL referrals and word-of-mouth expanding adoption of CyPath® Lung outside of the beta market launch in Texas SAN ANTONIO / May 15, 2024 /... Read More

SAN ANTONIO / May 02, 2024 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news. CyPath ® Lung Sales Ramp Up Month over Month Sales of CyPath ® Lung , our noninvasive diagnostic test for the early detection of lung cancer, continue to climb, with April sales up 21% over March. Physicians outside of Texas are also signing up with our wholly owned subsidiary, Precision Pathology... Read More

Collaboration with the US Department of Defense’s largest military health organization underway SAN ANTONIO / Apr 24, 2024 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced David Elzi, Ph.D., has been named Vice President of Product... Read More

SAN ANTONIO / Apr 09, 2024 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer... Read More

SAN ANTONIO / Apr 01, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease, today reported financial results for the three and 12 months ended December 31, 2023. Fiscal Year 2023 and Recent Highlights Reported fiscal year 2023 revenue of $2.5 million, a significant increase... Read More

SAN ANTONIO / Mar 08, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW ) today announced it has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct... Read More

SAN ANTONIO / Mar 06, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW ) today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered... Read More

Increasing physician interest, newly approved reimbursement code driving growth SAN ANTONIO / Mar 05, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported accelerating growth of 375% in CyPath ® Lung tests ordered and processed over the past three months as... Read More

SAN ANTONIO / Feb 21, 2024 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news. Lung Innovations Network Adds CyPath® Lung Test to its Comprehensive Lung Care Practice Lung Innovations Network is incorporating CyPath® Lung, our noninvasive... Read More

SAN ANTONIO / Feb 06, 2024 / Business Wire / Pharmaceuticals , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer including CyPath® Lung, today announced that Sandeep Bansal, M.D., Medical Director of Lung Innovations Network , has joined the Company’s Medical and Scientific Advisory Board to provide expert advice and counsel on bioAffinity... Read More

SAN ANTONIO / Jan 30, 2024 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news. Precision Pathology Laboratory Services Passes Biannual Inspection for CAP Accreditation Precision Pathology Laboratory Services (PPLS), a bioAffinity... Read More

Indian Patent Office Grants Patent Related to Porphyrin Compounds for Targeted Cancer Treatment SAN ANTONIO / Jan 23, 2024 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that India’s Office of the Controller General of Patents, Designs and Trade Marks... Read More

SAN ANTONIO / Jan 08, 2024 / Business Wire / Here is a summary of the latest news about bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease. bioAffinity Technologies (BIAF) and CyPath® Lung Featured on Bloomberg TV, National Podcasts and Upcoming Webinar bioAffinity Technologies ’ President and CEO... Read More

SAN ANTONIO / Dec 05, 2023 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today announced the appointment of Jamie Platt, Ph.D., to its Board of Directors effective Dec. 1, 2023. Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets.... Read More

SAN ANTONIO, / Nov 30, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar... Read More

SAN ANTONIO / Nov 28, 2023 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D., bioAffinity Technologies Vice President of Research, has been named to the Membership Committee of the American Society for Cell Biology (ASCB). First... Read More

SAN ANTONIO, Texas / Nov 15, 2023 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today launched a campaign in partnership with the American Cancer Society (ACS) to increase lung cancer screening in Texas. “ The Power of Three ” campaign emphasizes the importance of... Read More

SAN ANTONIO / Nov 14, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and nine months ended Sept. 30, 2023, and provided a business update. Highlights from the third quarter of 2023 and subsequent weeks included: Corporate... Read More

SAN ANTONIO / Nov 06, 2023 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales. Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive... Read More

CEO Maria Zannes to hold one-on-one investor meetings and present a corporate update highlighting commercial strategy SAN ANTONIO, Texas / Oct 10, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that Maria Zannes, President and CEO, will be participating in the 8 th Annual Dawson... Read More

Transformative Strategic Transaction Supports Commercialization of CyPath ® Lung Precision Pathology Founder Dr. Roby Joyce Joins bioAffinity’s Board of Directors Conference Call at 4:30 p.m. Eastern time Today SAN ANTONIO, Texas / Sep 19, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the... Read More

SAN ANTONIO / Sep 07, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that Maria Zannes, President and CEO, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25 th Annual Global Investment Conference being held September 11-13,... Read More

SAN ANTONIO / Aug 14, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and six months ended June 30, 2023, and provided a business update. Highlights from the second quarter of 2023 and subsequent weeks included: Corporate... Read More

SAN ANTONIO, Texas / Jul 12, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that the American Medical Association (AMA) has released a Current Procedural Terminology (CPT) code specifically for use with CyPath ® Lung, a noninvasive test for early-stage lung cancer. Created and... Read More

SAN ANTONIO, Texas / Jun 15, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for early-stage cancer detection and broad-spectrum cancer therapeutics, will present the poster “Vitamin B12 deprivation does not phenocopy selective cytotoxicity of CD320 and LRP2 silencing” at the University of Massachusetts (UMass) T.H. Chan Medical School’s fifth annual... Read More

SAN ANTONIO / May 22, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today will present the poster “Development of porphyrin-stained polystyrene compensation beads for use on an automated analysis platform” at CYTO 2023 , the annual Congress for the International... Read More

SAN ANTONIO / May 15, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three months ended March 31, 2023. Highlights from the first quarter of 2023 and subsequent weeks included: Corporate and Commercial Highlights Appointed... Read More

SAN ANTONIO / May 01, 2023 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced that Michael Dougherty has joined the company as Chief Financial Officer, effective today. Mr. Dougherty is an experienced C-level executive with more than 20 years in financial management and... Read More

SAN ANTONIO / Apr 25, 2023 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will present at the Cleveland Clinic’s invitation-only Advances in Early Lung Cancer Detection annual symposium in Cleveland, Ohio, on April 27, 2023. The presentation by Vivienne I. Rebel, MD, PhD, bioAffinity... Read More

SAN ANTONIO / Apr 05, 2023 / Business Wire / bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will ring the Nasdaq Stock Market closing bell this afternoon to commemorate the Company’s 2022 initial public offering (IPO). “Thank you to Nasdaq for giving us the opportunity to participate in one of Wall... Read More

Conference Call Scheduled for April 3, 2023, at 9:00 a.m. Eastern Time SAN ANTONIO / Mar 31, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and 12 months ended December 31, 2022. Financial Highlights Raised net proceeds of... Read More

SAN ANTONIO / Mar 28, 2023 / Business Wire / bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) today announced the publication of a paper titled “Porphyrin-modified beads for use as compensation controls in flow cytometry” in the peer-reviewed Journal of Visualized Experiments (JoVE) . The paper describes the protocol for preparing porphyrin-labeled compensation beads to optimize the results of bioAffinity’s CyPath ®... Read More

Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time SAN ANTONIO / Mar 24, 2023 / Business Wire / bioAffinity Technologies , Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results... Read More

Noninvasive Test Developed Using Machine Learning Detects Early-Stage Lung Cancer with High Sensitivity and Specificity SAN ANTONIO / Jan 25, 2023 / Business Wire / bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) today announced publication of “ Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning ” detailing results of the Company’s clinical trial for its non-invasive... Read More

bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “ Porphyrin Compounds and Compositions Useful for Treating Cancer ” for the targeted delivery of novel cancer treatments. A Notice of Allowance is issued after the USPTO makes a determination that a patent should be granted for the claimed... Read More

NEW YORK , Dec. 19, 2022 /PRNewswire/ -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF) Click Here to view full Argus Equity Research Report. COMPANY HIGHLIGHTS: Excerpts (as conveyed by Argus Analyst Steve Silver ) include: BIAF: A Potential Advance in the Early Detection of Cancer In our view, bioAffinity is well... Read More

SAN ANTONIO--( BUSINESS WIRE )-- bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment, today announced that they have made a key promotion and additions to their staff. Jennifer Rebeles, Ph.D., has been promoted to Vice President of Diagnostics. Dr. Rebeles joined... Read More

Awarded patents protect novel porphyrin conjugated compounds for selective delivery of cancer treatments bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced the People’s Republic of China awarded a Certificate of Patent to the Company’s wholly owned subsidiary OncoSelect ® for its patent “ Porphyrin Compounds and Compositions Useful for Treating Cancer ” that is directed to novel compounds in which porphyrins are... Read More

Powerful platform reveals the lung environment for diagnosing lung diseases bioAffinity Technologies , Inc., (NASDAQ: BIAF; BIAFW) will present results of its research into the use of flow cytometry for analyzing the lung environment to detect diseases of the lung at the American College of Chest Physicians (CHEST) 2022 conference Oct. 16-19, 2022. The presentation, Sputum Analysis By Flow Cytometry To Assess Lung Health ,... Read More

bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities. Investors participating in bioAffinity Technologies’ financing exercised a total of 725,576 tradeable warrants at a price of $7.35 per share and... Read More

bioAffinity Technologies , (NASDAQ: BIAF, BIAFW), a biotechnology company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, today announced publication of its research in high-throughput flow cytometry analysis of sputum. The journal PLOS ONE , published Sputum analysis by flow cytometry; an effective platform to analyze the lung environment reporting on results of analyzing sputum... Read More

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today bioAffinity Technologies , Inc. ("bioAffinity" or the "Company") (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, has completed its previously announced initial public offering ("IPO") of 1,282,600 units, each... Read More

bioAffinity Technologies, Inc. (“bioAffinity” or the “Company”) (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today it has completed its previously announced initial public offering (“IPO”) of 1,282,600 units, each consisting of one share of common stock, one... Read More